Market Outlook

By 2035, the U.S. Diabetic Retinopathy Screening Devices Market is expected to reach approximately USD 2.45 billion, expanding at a CAGR of 13.50% during the forecast period 2026–2035. The market was valued at approximately USD 0.69 billion in 2025, following expansion from an estimated USD 0.42 billion in 2021, USD 0.47 billion in 2022, USD 0.53 billion in 2023, and USD 0.60 billion in 2024. Values in this report are expressed in USD billions.

The U.S. diabetic retinopathy screening devices industry is entering a structural growth phase as retinal screening moves beyond ophthalmology practices into primary care, endocrinology clinics, federally qualified health centers, integrated delivery networks, retail-oriented care sites, and community screening programs. The underlying clinical need is substantial. More than 40 million people in the United States are estimated to have diabetes, while approximately 9.6 million Americans were already living with diabetic retinopathy in 2021, including around 1.84 million with vision-threatening disease.

The addressable screening population is materially larger than the diagnosed diabetic retinopathy population because screening is intended to identify disease before symptoms or advanced retinal damage become apparent. U.S. diabetes-management guidelines recommend retinal evaluation beginning at diagnosis for people with type 2 diabetes and within five years after onset for adults with type 1 diabetes. Consequently, the commercial opportunity is linked not only to retinal disease prevalence but to the much larger pool of people requiring recurring diabetic eye surveillance.

A major market constraint is the persistent screening gap. A substantial proportion of people with diabetes do not receive recommended annual eye care, particularly younger adults, patients in rural communities, populations facing transportation or specialist-access barriers, and patients managed principally within primary care. This gap is creating a commercial opening for non-mydriatic cameras, handheld retinal imaging, teleophthalmology networks, autonomous artificial intelligence systems, and integrated screening workflows capable of producing actionable results during the patient’s existing diabetes-care encounter.

The market’s value mix is therefore changing. Conventional tabletop fundus cameras remain important, but incremental revenue is increasingly associated with autonomous AI interpretation, portable imaging, cloud connectivity, electronic health record integration, recurring software fees, remote quality assurance, and service-based deployment models. The three autonomous AI platforms recognized within current U.S. diabetes-care standards—AEYE-DS, EyeArt, and LumineticsCore—demonstrate that AI-based screening has moved from experimental ophthalmic technology into a regulated clinical workflow.

Hospital and physician purchasing decisions are also becoming more economic. A retinal screening platform is increasingly evaluated according to the number of eligible diabetic patients that can be screened, percentage of interpretable examinations, staff training requirement, time per examination, referral conversion, HEDIS and quality-measure impact, reimbursement capture, EHR connectivity, capital intensity, and incremental specialist workload. Devices capable of increasing screening completion without creating an equivalent increase in ophthalmologist labor are positioned to capture disproportionate value through 2035.

 

Introduction

According to the U.S. Diabetic Retinopathy Screening Devices Market Report, the sector is evolving from an ophthalmology-centered imaging market into a distributed diagnostic infrastructure market. Historically, screening was heavily dependent on dilated examinations performed by optometrists or ophthalmologists. That approach remains clinically important, particularly when disease is detected or when comprehensive ocular evaluation is required, but the scale of the diabetes population has created a need for additional access models.

The most important distinction in this market is between screening and definitive ophthalmic management. Retinal photography, autonomous AI and teleophthalmology can identify patients requiring referral and can substantially improve access to diabetic eye evaluation, but abnormal findings, poor-quality images and clinically complex cases continue to require eye-care professionals. Screening technology therefore creates value primarily by separating large numbers of low-risk patients from the smaller group requiring specialist attention.

This workflow has important economic implications. The United States had approximately 29.1 million people with diagnosed diabetes in 2023, and approximately 1.5 million new adult cases were diagnosed during that year. The annual addition of newly diagnosed patients continuously refreshes the screening pool, while established patients require repeat surveillance according to clinical risk. Unlike one-time diagnostic markets, diabetic retinopathy screening therefore has a recurring demand structure.

The disease burden is also geographically uneven. National surveillance has estimated that diabetic retinopathy prevalence among people with diabetes varies materially across states, ranging from approximately 20.8% to 31.3% in modeled 2021 estimates. Screening access also differs across rural and urban markets. This variation creates different purchasing requirements: high-throughput tabletop systems can be economically attractive in urban integrated networks, whereas handheld cameras, teleophthalmology and autonomous AI have stronger value propositions in geographically dispersed populations.

The market model in this report includes dedicated retinal cameras used for diabetic screening, portable and handheld fundus imaging systems, the diabetic-retinopathy-attributable portion of advanced retinal imaging equipment, FDA-authorized autonomous AI diagnostic platforms, remote-reading and screening workflow software, and related connectivity used to deliver diabetic retinal screening. It excludes anti-VEGF pharmaceuticals, retinal laser treatment, vitrectomy equipment, surgical instruments, general ophthalmic diagnostics unrelated to DR screening, and treatment-monitoring revenue that cannot reasonably be attributed to screening.

From 2026 through 2035, market leadership will increasingly depend on the ability to connect image acquisition, automated interpretation, quality measurement, referral management and longitudinal patient tracking. Vendors selling a camera alone will face increasing competition from platforms capable of proving that more patients were actually screened and that clinically significant findings successfully entered an eye-care pathway.

 

Key Market Drivers: What’s Fueling the U.S. Diabetic Retinopathy Screening Devices Market Boom?

The first and most durable driver is the scale of diabetes in the United States. Current national estimates indicate that approximately 40.1 million Americans have diagnosed or undiagnosed diabetes, representing about 12% of the U.S. population. Around 11 million adults with diabetes are estimated to remain undiagnosed, illustrating the continuing expansion potential of the clinical diabetes population. As diagnosis improves, newly identified patients enter recommended retinal screening pathways.

The second driver is the substantial existing diabetic retinopathy burden. Approximately 9.6 million Americans were estimated to have diabetic retinopathy in 2021, while roughly 1.84 million had vision-threatening diabetic retinopathy. Among adults aged 40 years or older, approximately 8.94 million were estimated to have DR. This is especially important commercially because retinal damage can progress before noticeable vision loss, making systematic screening economically more defensible than symptom-triggered evaluation.

The third driver is the persistent gap between recommended screening and actual care delivery. U.S. public health guidance continues to identify inadequate annual eye examination among people with diabetes as a major preventive-care problem. The traditional model requires a separate eye-care appointment, transportation, specialist availability and successful referral completion. Every additional step creates attrition. Point-of-care retinal imaging can compress the process into a diabetes visit that the patient is already attending.

The fourth driver is formal acceptance of retinal photography and FDA-authorized AI within U.S. clinical guidance. Current diabetes standards specifically recognize retinal photography with remote reading and FDA-authorized artificial intelligence as appropriate approaches for increasing access to diabetic retinopathy screening. This substantially improves the procurement environment because health-system buyers are no longer evaluating autonomous AI solely as an experimental technology.

The fifth driver is reimbursement and quality-measure alignment. CPT 92229 created a defined pathway for autonomous point-of-care retinal imaging and interpretation, while diabetic eye examination remains an important health-plan quality measure. For primary care networks, accountable care organizations and Medicare-oriented populations, screening devices can therefore influence both fee-for-service economics and quality performance. This is strategically important because the purchasing decision can be supported by revenue capture and care-gap closure rather than relying only on an ophthalmology capital-equipment budget.

The sixth driver is primary-care decentralization. Autonomous retinal screening can be performed by appropriately trained non-eye-care staff when used within its cleared indications. This changes the labor equation. A clinic does not need an ophthalmologist physically present for every negative screening encounter, allowing eye specialists to concentrate on positive findings and patients requiring treatment.

The seventh driver is device miniaturization. Handheld retinal cameras reduce the dependency on dedicated dark rooms, fixed ophthalmic workstations and high-volume specialist locations. Portable screening can be deployed across endocrinology offices, multisite primary care groups, rural clinics, mobile health programs and community-based sites. The first FDA-cleared combination of a handheld fundus camera with autonomous DR artificial intelligence demonstrated that portability and autonomous interpretation can operate within the same regulated workflow.

The eighth driver is clinical workflow interoperability. Screening devices increasingly need to communicate with EHRs, automatically return diagnostic results, support referral orders and populate quality-measure documentation. As health systems become more digitally integrated, interoperability can carry as much procurement weight as camera specifications. Platforms that reduce manual charting and eliminate disconnected imaging workflows are positioned to achieve greater enterprise penetration.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Artificial intelligence is the market’s most consequential innovation cycle. The first generation of digital retinal screening largely transferred photographs to human graders. The emerging model allows FDA-authorized software to determine whether the patient has disease meeting a defined referral threshold. This reduces interpretation latency from days to minutes and enables the screening episode to conclude while the patient remains in the clinic.

Performance is moving toward clinically practical thresholds rather than laboratory-only accuracy. Current autonomous systems have demonstrated sensitivity above 90% in major U.S. clinical evaluations, while leading platforms can generate results within approximately one minute. EyeArt’s pivotal evaluation reported high sensitivity for more-than-mild and vision-threatening retinopathy, while newer portable AI configurations have demonstrated diagnostic sensitivity in the low-90% range with imageability above 99% in reported clinical programs.

Portable imaging represents a second major innovation vector. Historically, retinal photography required tabletop equipment, controlled positioning and trained ophthalmic staff. Handheld systems increasingly combine wide fields of view, non-mydriatic acquisition, automated exposure and cloud-linked AI. This expands the commercial addressable market from ophthalmology offices toward primary care and community health.

A third innovation area is robotic and automated image acquisition. Automated alignment, autofocus, auto-capture and patient-positioning assistance reduce technician dependence and improve consistency. This matters economically because image quality is one of the hidden constraints on screening programs. A low-cost camera that repeatedly generates ungradable examinations can create greater downstream cost than a more automated system with higher first-pass imageability.

Ultra-widefield retinal imaging is also gaining relevance. Conventional fundus photography captures a limited retinal field, whereas ultra-widefield systems can visualize substantially more peripheral retina. Peripheral lesions can provide additional clinical information in diabetic retinopathy assessment. These systems remain concentrated within ophthalmology and retina settings because of their higher capital cost, but their value is increasing for comprehensive risk assessment and specialist triage.

Optical coherence tomography is another strategic component, particularly when diabetic macular edema is suspected. OCT is not a replacement for standard DR screening in every patient, and including all OCT revenue would materially overstate this market. However, OCT increasingly supports the secondary evaluation of patients with suspicious retinal findings and forms part of integrated diabetic eye-care pathways. Compact and automated OCT platforms could therefore expand the screening-related addressable share of the modality.

Manufacturers are additionally shifting toward recurring revenue. Equipment-as-a-service, monthly subscription, per-exam AI pricing, software licensing, cloud storage, remote support and managed screening programs reduce upfront capital barriers. This model is well suited to primary care organizations that may have thousands of diabetic patients but lack an ophthalmic equipment budget.

The ultimate competitive frontier will be closed-loop screening. A high-performing platform will not merely produce an image or AI result. It will identify the eligible patient, conduct the examination, document the result, update the quality measure, initiate the correct referral, confirm specialist follow-through and make the screening status visible to the health system. Vendors that control more of this workflow can support higher lifetime account value and stronger customer retention.

 

Segmentation Insights

The U.S. Diabetic Retinopathy Screening Devices Market is segmented on the basis of product type, device modality, screening approach, end user and region.

 

By Product Type

Non-Mydriatic Fundus Cameras

Non-mydriatic fundus cameras represent the largest dedicated hardware category because they combine established retinal imaging with relatively efficient workflow. These systems are widely used across optometry, ophthalmology, diabetes clinics and screening programs. Automated alignment and autofocus are increasing their suitability for staff who are not ophthalmic photographers. Their competitive position is strengthening as autonomous AI platforms become compatible with mainstream camera models.

AI-Enabled Diabetic Retinopathy Screening Platforms

AI-enabled screening platforms are expected to be the fastest-growing product category through 2035. The segment includes regulated autonomous diagnostic algorithms, associated software, cloud infrastructure and integrated camera-AI solutions. Revenue growth is driven by recurring per-exam or subscription economics, primary-care expansion and the ability to generate diagnostic outputs without routine specialist interpretation. AI screening is expected to move from a minority share of 2025 market revenue toward one of the largest value pools by the end of the forecast period.

Optical Coherence Tomography and OCT Angiography Systems

OCT and OCTA systems contribute primarily within ophthalmology, retina and higher-acuity diagnostic pathways. Their DR-screening-attributable revenue is smaller than their overall ophthalmic market because much of OCT utilization relates to treatment monitoring, macular degeneration and glaucoma. Nevertheless, diabetic macular edema assessment and increasingly automated image analysis support continued expansion of this subsegment.

Ultra-Widefield and Multimodal Retinal Imaging Systems

Ultra-widefield systems command premium pricing and are concentrated in specialist settings. Their ability to capture extensive peripheral retinal anatomy makes them valuable for detecting lesions that can be missed by narrower imaging fields. Integrated platforms combining fundus imaging, OCT, angiography or scanning laser technologies are especially attractive to large retina groups and academic medical centers where equipment utilization can be spread across multiple disease pathways.

Portable, Smartphone-Connected and Other Screening Systems

Portable cameras, smartphone-enabled retinal imaging, screening accessories and compact integrated systems form a smaller but rapidly expanding category. Their economics are strongest where conventional ophthalmic infrastructure is absent. Improvements in optics, automated capture and AI compatibility are gradually moving these technologies from outreach applications into routine clinical workflows.

 

By Device Modality

Tabletop and Desktop Systems

Tabletop systems currently account for the majority of installed clinical imaging capacity because they provide stable image quality, standardized positioning and integration with established ophthalmic workflows. Large endocrinology groups and integrated primary care networks are also adopting automated tabletop cameras when annual screening volumes justify a permanent installation.

Handheld Systems

Handheld screening is forecast to gain the most share over the next decade. Portability changes the deployment model from “patient travels to imaging” to “imaging travels to the patient.” This has particular relevance for multisite physician networks, nursing-supported diabetes programs, rural care, mobile screening and environments with limited dedicated floor space.

Smartphone-Connected Systems

Smartphone-based imaging offers attractive hardware economics and can extend screening to community or resource-constrained locations. Its U.S. growth will depend on consistent image quality, regulatory positioning, cybersecurity, workflow integration and payer acceptance. The strongest opportunity is likely to be in supervised screening programs rather than unrestricted consumer self-testing.

Mobile and Distributed Screening Configurations

Mobile screening vans, rotating equipment programs and distributed screening fleets address populations that have difficulty accessing ophthalmology. These configurations may use tabletop, handheld or portable imaging equipment, but commercially they operate through a different utilization model. Population-health contracts and payer-sponsored outreach could make this segment increasingly important in states with large rural or underserved populations.

 

By Screening Approach

Autonomous AI Point-of-Care Screening

Autonomous AI is expected to record the strongest CAGR among screening approaches. It allows an eligible patient to be imaged during an existing primary-care or diabetes encounter and receive an immediate diagnostic disposition. The economic value is strongest when the platform closes a documented eye-care gap and avoids unnecessary specialist appointments for negative cases.

Teleophthalmology and Remote Human Grading

Teleophthalmology remains an important U.S. model, particularly within public health programs, Veterans-oriented care, FQHC networks and geographically dispersed populations. Images are acquired locally and transmitted to ophthalmologists, optometrists or certified graders. The model preserves human interpretation while reducing the need for patient travel, although turnaround time and reading capacity can constrain scale.

Specialist-Led Digital Screening

Ophthalmology and optometry practices remain core screening locations. Their advantage is immediate access to comprehensive examinations, OCT, dilation and treatment referral. Growth is slower than autonomous primary-care screening but the specialist segment remains essential for high-risk patients and for screening individuals whose images are ungradable or whose clinical history falls outside autonomous-AI indications.

AI-Assisted Specialist Triage

AI-assisted triage differs from autonomous diagnosis because software prioritizes or supports human interpretation rather than independently completing the examination. This model is attractive to large retinal image volumes, teleophthalmology networks and ophthalmology groups looking to improve grader productivity while maintaining clinician oversight.

 

By End User

Ophthalmology, Retina and Optometry Practices

Eye-care practices remain the largest end-user segment by installed equipment value. They purchase higher-specification cameras, OCT systems, ultra-widefield platforms and integrated imaging networks. Their procurement priorities include image quality, diagnostic depth, multimodal capability, service reliability and integration with ophthalmic electronic records.

Primary Care and Endocrinology Practices

Primary care and endocrinology represent the most strategically important growth channel. These clinics already manage the patients who require diabetic eye screening, allowing imaging to occur without a separate appointment. Autonomous AI and simplified non-mydriatic imaging make this workflow increasingly practical. By 2035, this channel is expected to capture a substantially greater proportion of screening volume than in 2025.

Hospitals and Integrated Delivery Networks

Hospitals and IDNs can deploy screening across primary care, endocrinology, ophthalmology and population-health divisions under a common enterprise contract. Their purchasing processes are more complex, but successful vendors can secure larger multiyear deployments. Interoperability, cybersecurity, EHR integration, quality reporting and standardized referral protocols are particularly important.

Federally Qualified Health Centers and Community Care

FQHCs and community health organizations address populations that frequently experience barriers to specialty eye care. Portable retinal imaging and AI can significantly reduce referral friction. Grants and public-health funding remain relevant, but reimbursement-backed models are improving commercial sustainability compared with screening programs dependent exclusively on external funding.

Payer, Retail, Mobile and Population-Health Programs

Health plans, retail clinics, mobile screening organizations and population-health vendors represent an emerging channel. Their incentive is frequently quality-gap closure rather than ophthalmic procedure revenue. Successful platforms must combine portable technology with reliable documentation, high screening completion and an effective pathway for positive patients to reach eye-care specialists.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Diabetic Retinopathy Screening Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional demand is shaped by diabetes prevalence, population scale, screening adherence, rurality, concentration of endocrinologists and eye-care providers, Medicare exposure, health-system consolidation, FQHC density, digital-health adoption and the capacity to implement autonomous AI.

The South represents the largest regional market in 2025, while the West is expected to record the fastest technology-driven growth through 2035. The Northeast has a highly sophisticated eye-care and academic infrastructure, while the Midwest combines large established health systems with substantial rural screening opportunities.

South

The South represented an estimated USD 0.25 billion in 2025, or approximately 36% of the national market. Under the current forecast, regional revenue could approach USD 0.90 billion by 2035. The region includes Texas, Florida, Georgia, North Carolina, Tennessee, South Carolina, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, Virginia, Maryland, West Virginia and the District of Columbia for purposes of this report.

The South’s leadership reflects both population size and disease burden. Texas and Florida create exceptionally large screening pools because of their scale, substantial Medicare populations and extensive networks of primary-care, endocrinology and ophthalmology providers. Houston, Dallas-Fort Worth, Austin, San Antonio, Miami, Tampa, Orlando and Jacksonville support high-volume commercial deployment opportunities across multispecialty medical groups and IDNs.

Florida is especially attractive for diabetic retinal screening because of its older population. Older adults have greater cumulative diabetes exposure and therefore greater risk of retinal complications. Autonomous systems can be commercially valuable within Medicare-oriented physician networks where preventive-care metrics and specialist capacity are closely managed.

Texas combines metropolitan scale with large rural territories. This creates two distinct procurement environments: advanced imaging platforms in Houston and Dallas medical centers, and portable or teleophthalmology models across smaller communities and border-region populations.

North Carolina, Georgia, Tennessee, Virginia and Maryland offer strong integrated health-system and academic-center adoption. These states are likely to become important proving grounds for enterprise AI deployment because large networks can embed retinal screening across dozens of primary-care locations and centralize referral management.

Alabama, Mississippi, Louisiana, Kentucky and West Virginia are strategically important despite smaller medical-device revenue bases. Historical U.S. screening data have demonstrated persistent eye-care access gaps in several of these states. High chronic-disease burden combined with rurality increases the value proposition for portable retinal cameras, remote reading and autonomous AI. The commercial challenge is creating a deployment model with sufficiently low per-site cost.

Arkansas and Oklahoma share similar rural-access characteristics, while South Carolina continues to benefit from population growth and expanding healthcare infrastructure. Across the South, manufacturers that combine hardware financing, staff training, reimbursement workflow and tele-retina referral support are likely to outperform vendors offering equipment-only contracts.

West

The West accounted for an estimated USD 0.17 billion in 2025 and could exceed USD 0.65 billion by 2035, making it the fastest-growing regional market. The region includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the largest state opportunity in the region. Its scale, concentration of technology-oriented health systems, large diabetic population, sophisticated specialist networks and strong digital-health ecosystem make it particularly receptive to AI-enabled screening. Large multisite organizations can justify integration of autonomous imaging with enterprise EHR and referral platforms, while community-health networks create opportunities for portable systems.

Arizona and Nevada are important growth states because of rapid population expansion, significant retiree populations and increasing healthcare demand. Nevada also illustrates why disease prevalence alone cannot determine market attractiveness. National DR modeling has shown state-level prevalence among people with diabetes ranging from approximately 20.8% in Nevada to 31.3% in Massachusetts, yet Nevada can still represent a strong device opportunity because screening infrastructure and population growth influence commercial demand separately from disease prevalence.

Washington, Oregon, Colorado and Utah have sophisticated delivery networks and relatively strong adoption of digitally integrated care. These states are attractive for AI-assisted workflow, EHR-connected diagnostic platforms and population-health screening programs.

New Mexico, Idaho, Montana, Wyoming and Alaska have smaller populations but disproportionately strong use cases for remote and portable technology because travel distances can make traditional eye-care referral difficult. Historical Medicare screening evidence identified particularly low examination rates in Alaska and Wyoming, underscoring the long-standing access problem. Hawaii presents a different geographic challenge, with inter-island access supporting remote imaging and hub-and-spoke interpretation.

The West’s strategic advantage is innovation velocity. Manufacturers frequently encounter health systems willing to evaluate new digital workflows, cloud platforms and portable technologies. For this reason, the region is expected to increase its national revenue share even though the South retains the largest absolute market.

Northeast

The Northeast represented approximately USD 0.15 billion in 2025 and is projected to approach USD 0.49 billion by 2035. For this report, the region includes New York, Massachusetts, Pennsylvania, New Jersey, Connecticut, Rhode Island, Maine, New Hampshire, Vermont and Delaware.

New York provides the largest commercial opportunity in the region because of its population density, broad hospital infrastructure and substantial diabetic patient pool. New York City supports advanced ophthalmology and retinal imaging, whereas upstate areas provide greater opportunities for distributed screening and teleophthalmology.

Massachusetts is strategically important because of its concentration of academic medical centers, health technology expertise and evidence-driven adoption environment. CDC modeling estimated that Massachusetts had the highest crude state-level diabetic retinopathy prevalence among people with diabetes in the referenced 2021 analysis, at approximately 31.3%. This reinforces the clinical importance of systematic retinal surveillance even within states possessing advanced medical infrastructure.

Pennsylvania and New Jersey offer large health-system and physician-network opportunities. Pennsylvania also contains significant rural populations outside major metropolitan centers, increasing the relevance of portable screening. Connecticut and Rhode Island have relatively dense medical infrastructure and historically stronger eye-examination utilization among Medicare beneficiaries, making their markets more oriented toward technology replacement and workflow efficiency rather than first-time access.

Maine, Vermont and New Hampshire have smaller absolute markets but favorable use cases for teleophthalmology because of dispersed populations. Delaware is a compact market where integrated payer-provider programs and Medicare-focused screening can support targeted deployments.

Procurement in the Northeast tends to be clinically rigorous. Academic systems and large IDNs frequently require validation data, cybersecurity review, EHR integration, defined referral responsibility and evidence that autonomous screening will not generate unnecessary ophthalmology workload. This can lengthen sales cycles but creates strong account durability once a platform is standardized.

Midwest

The Midwest represented approximately USD 0.12 billion in 2025 and is projected to reach around USD 0.39 billion by 2035. The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

Illinois and Ohio are the largest state markets, supported by major metropolitan health systems, academic centers and large chronic-disease populations. Chicago, Cleveland, Columbus and Cincinnati contain extensive primary-care and specialty networks capable of supporting enterprise retinal screening programs.

Michigan has substantial diabetes-management demand across both urban and rural populations. Health systems that span Detroit and smaller communities can benefit from standardized screening equipment combined with centralized ophthalmology referral. Minnesota has a distinctive advantage through its mature medical-technology ecosystem and sophisticated integrated providers, making it an attractive market for advanced retinal imaging and AI workflow experimentation.

Indiana, Wisconsin and Missouri provide stable screening-device demand with significant opportunities in community medicine. Iowa, Kansas and Nebraska are particularly suited to teleophthalmology and portable imaging because patients outside metropolitan areas may face longer travel requirements for specialist care.

North Dakota and South Dakota are smaller device markets by revenue but relevant for decentralized screening. In these states, the commercial objective is unlikely to be maximizing equipment sales at each facility; instead, manufacturers can create value through shared equipment, mobile programs, subscription models and remote interpretation.

The Midwest is expected to expand slightly below the national CAGR because its population growth is slower than the South and West. Nevertheless, the region provides an attractive combination of large IDNs, established diabetes programs and underserved rural populations. Contracting discipline, reliability and strong clinical implementation support will be particularly important for manufacturers seeking durable share.

 

Key Market Players

The U.S. Diabetic Retinopathy Screening Devices Competitive Landscape is fragmented across ophthalmic imaging manufacturers, autonomous AI developers, teleophthalmology providers and portable-camera companies. Unlike traditional medical-device categories, competitive advantage increasingly comes from combining hardware and software rather than controlling a single equipment category.

Approximately 20–25 companies with direct or adjacent relevance to U.S. diabetic retinopathy screening include Topcon Healthcare, Digital Diagnostics, Eyenuk, AEYE Health, Optomed, Carl Zeiss Meditec, Canon U.S.A./Canon Medical Systems, NIDEK, Heidelberg Engineering, Kowa American Corporation, Revenio Group/CenterVue, Baxter through Welch Allyn ophthalmic imaging solutions, Visionix, Optovue technologies within AMETEK’s ophthalmic portfolio, Volk Optical, Remidio, Forus Health, EyePACS, VisionQuest Biomedical, RetinAI, Altris AI, iCare, Phoenix Technology Group and Tomey.

Topcon holds a particularly influential hardware position because its non-mydriatic retinal cameras are used with multiple digital diagnostic workflows. Digital Diagnostics remains strategically significant because IDx-DR, now marketed as LumineticsCore, established the U.S. regulatory pathway for autonomous AI diagnosis of diabetic retinopathy.

Eyenuk competes through the EyeArt platform, which can autonomously detect more-than-mild diabetic retinopathy and vision-threatening diabetic retinopathy. Its multi-camera positioning is strategically important because health systems may prefer AI that can operate across existing imaging fleets.

AEYE Health has become an important disruptor through autonomous AI combined with tabletop and portable retinal cameras. Its partnership with Optomed enabled the first FDA-cleared handheld autonomous AI diabetic retinopathy screening configuration, directly addressing the portability constraint that previously limited primary-care deployment.

ZEISS, Heidelberg Engineering, NIDEK, Canon, Kowa and other established ophthalmic manufacturers retain strong competitive positions in specialist imaging. Their advantage is clinical trust, installed base, image quality, service infrastructure and broader ophthalmic portfolios. However, they face increasing pressure to integrate AI and cloud workflows into traditionally hardware-oriented businesses.

Competition through 2035 will be driven by six capabilities: regulatory evidence, imageability in real-world patients, diagnostic accuracy, ease of operation by non-specialists, interoperability with EHR and quality systems, and economics per completed screening. Vendors able to demonstrate high screening completion and referral closure rather than merely strong algorithm performance will have the strongest negotiating position with health systems and payers.

 

Recent Developments

The most important recent development has been continued regulatory and commercial maturation of autonomous artificial intelligence. U.S. diabetes-care standards for 2026 recognize three FDA-authorized AI platforms for diabetic retinopathy screening: AEYE-DS, EyeArt and LumineticsCore. Their inclusion establishes autonomous AI as a clinically recognized alternative screening pathway rather than a fringe digital-health application.

In April 2024, AEYE-DS received FDA 510(k) clearance for use with the Optomed Aurora handheld fundus camera. The combination was positioned as the first FDA-cleared handheld autonomous AI solution for diabetic retinopathy detection. Clinical studies supporting the platform reported sensitivity in approximately the 92%–93% range, specificity of approximately 89%–94%, and diagnostic output for more than 99% of tested patients.

During 2025, competition increasingly shifted toward camera compatibility and workflow simplicity. AEYE Health and Topcon reported clinical results involving AEYE-DS with Topcon’s automated retinal imaging platform, illustrating the industry’s movement toward systems that reduce manual alignment and make screening practical for primary-care staff.

During 2026, EHR integration became a more prominent competitive feature. AEYE Health expanded integration with Epic-oriented workflows, allowing diabetic retinal screening orders and results to move through the clinical record rather than remain in a separate ophthalmic system. This direction is strategically important because major IDNs increasingly view interoperability as a prerequisite for scaling screening beyond a pilot location.

The industry is also moving from capital purchases toward service-based contracting. Portable systems can increasingly be deployed through fixed monthly fees or subscription models, while AI platforms generate recurring software revenue. This lowers the barrier for primary-care clinics that cannot justify purchasing conventional ophthalmic equipment but manage a substantial number of diabetic patients.

The next competitive cycle is likely to center on broader retinal intelligence, although regulatory boundaries will remain critical. Developers are researching retinal biomarkers for additional ocular and systemic conditions, but U.S. commercialization must remain aligned with specific cleared indications. Vendors that successfully expand indications without compromising diagnostic reliability could increase revenue per captured retinal image.

 

Conclusion

The U.S. Diabetic Retinopathy Screening Devices Market Size & Share is positioned to expand from approximately USD 0.69 billion in 2025 to USD 2.45 billion by 2035, representing a 13.50% CAGR from 2026 through 2035. The growth profile is materially stronger than that of conventional ophthalmic hardware because the market is being reshaped by autonomous artificial intelligence, portable retinal imaging, recurring software economics and expansion into primary-care settings.

The clinical foundation is substantial. More than 40 million Americans are living with diabetes, approximately 9.6 million people were estimated to have diabetic retinopathy in 2021, and approximately 1.84 million had vision-threatening disease. At the same time, screening remains inconsistent, producing a large gap between the number of people who should receive retinal evaluation and the number completing appropriate eye care.

The highest-growth opportunity is therefore not simply selling more fundus cameras to ophthalmologists. It is making retinal screening operationally feasible where diabetes care already occurs. Primary-care practices, endocrinology networks, FQHCs, integrated delivery systems and payer-supported screening programs are becoming increasingly important purchasers because autonomous AI can produce an actionable result without requiring an ophthalmologist to interpret every examination.

Traditional ophthalmic imaging vendors will remain essential because high-quality retinal capture is the foundation of screening and because positive or complex patients require specialist evaluation. However, competitive value will progressively move toward integrated platforms combining acquisition, AI, EHR connectivity, reimbursement documentation and referral management.

Regional opportunity will remain strongest in the South, where population scale, diabetes burden and uneven specialty access create the largest absolute screening market. The West is expected to achieve the fastest growth because of rapid population expansion and strong adoption of portable and digital-health technologies. The Northeast will remain a high-value, evidence-intensive market led by major academic and integrated systems, while the Midwest provides durable opportunities across large IDNs and underserved rural populations.

For manufacturers, investors and healthcare organizations evaluating this market, the central strategic question is no longer whether automated diabetic eye screening can work. The more important question is which platforms can transform clinical validation into reliable population-scale deployment. Market winners will be those capable of screening more eligible patients, producing consistently interpretable examinations, fitting into existing clinical workflows, documenting reimbursable care, closing quality gaps and directing positive patients to appropriate ophthalmic treatment.

By 2035, diabetic retinopathy screening in the United States is expected to operate less as a stand-alone ophthalmic procedure and more as an integrated component of routine diabetes management. That transition—from specialist-dependent retinal imaging toward distributed, connected and increasingly autonomous screening—is the primary economic force supporting the market’s movement toward approximately USD 2.45 billion over the forecast period.

 

TABLE OF CONTENT

1. U.S. Diabetic Retinopathy Screening Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Triangulation & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Retinal Imaging Device Manufacturers
1.6.2. Autonomous AI Diabetic Retinopathy Screening Developers
1.6.3. Ophthalmology, Retina and Optometry Practices
1.6.4. Primary Care and Endocrinology Networks
1.6.5. Hospitals and Integrated Delivery Networks
1.6.6. Federally Qualified Health Centers and Community Health Providers
1.6.7. Teleophthalmology and Remote Reading Providers
1.6.8. Health Plans, ACOs and Population Health Organizations
1.6.9. Distributors, Technology Integrators and Channel Partners
1.6.10. CMS, FDA, Payers and Clinical Decision-Makers

What this section provides: This section defines the U.S. diabetic retinopathy screening devices market boundary, addressable screening ecosystem, study methodology, assumptions, revenue inclusion criteria, stakeholder roles, and analytical framework used to measure and forecast the market.

2. U.S. Diabetic Retinopathy Screening Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, 2021–2035 (US$ Billion)
2.8. Growth Rate & CAGR Analysis, 2026–2035
2.9. High-Growth Opportunity Areas
2.9.1. Autonomous AI Point-of-Care Screening
2.9.2. Primary Care-Based Retinal Screening
2.9.3. Portable and Handheld Retinal Cameras
2.9.4. Teleophthalmology and Rural Screening
2.9.5. EHR-Integrated Screening Workflows
2.9.6. Population Health and Quality-Gap Closure Programs

What this section provides: This section gives decision-makers a concise view of market size, historical development, 2025 positioning, 2026–2035 growth trajectory, technology disruption, leading demand channels, and the commercial opportunity created by unmet diabetic eye-screening needs.

3. U.S. Diabetic Retinopathy Screening Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Diabetes Prevalence and Diagnosed Patient Population
3.1.2. Large and Growing Diabetic Retinopathy Screening-Eligible Population
3.1.3. Persistent Diabetic Eye Examination Compliance Gap
3.1.4. Expansion of Autonomous AI Screening in Primary Care
3.1.5. Increasing Adoption of Non-Mydriatic Retinal Imaging
3.1.6. Growth of Teleophthalmology and Remote Retinal Evaluation
3.1.7. HEDIS, Quality Measure and Population Health Incentives
3.1.8. Demand for Earlier Detection of Vision-Threatening Retinopathy
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Retinal Imaging Systems
3.2.2. Variable Reimbursement Economics Across Screening Models
3.2.3. Image Quality and Ungradable Examination Risk
3.2.4. Limited Workflow Integration Across Smaller Practices
3.2.5. Patient Referral Leakage After Positive Screening Results
3.2.6. Cybersecurity and Health Data Privacy Requirements
3.3. Opportunities and Their Impact Analysis
3.3.1. Autonomous AI Expansion Across Primary Care Networks
3.3.2. Handheld and Portable Screening Deployment
3.3.3. Rural and Underserved Population Screening
3.3.4. FQHC and Community Health Center Adoption
3.3.5. Medicare and Value-Based Care Screening Programs
3.3.6. Enterprise IDN Screening Standardization
3.3.7. Retail Health and Mobile Screening Models
3.3.8. Closed-Loop Referral and Patient Navigation Platforms
3.4. Challenges and Their Impact Analysis
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Screening Cost per Completed Examination Analysis
3.8. Specialist Capacity and Referral Economics Analysis
3.9. Health System Capital Procurement Behavior Analysis
3.10. Screening Completion and Patient Drop-Off Analysis

What this section provides: This section explains the clinical, demographic, economic, reimbursement, workflow and technology forces influencing screening-device adoption and helps clients distinguish durable market drivers from implementation constraints.

4. U.S. Diabetic Retinopathy Screening Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitution
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Retinal Camera Component and Manufacturing Ecosystem
4.6. Impact of Artificial Intelligence and Digitalization
4.7. Cloud-Based Retinal Image Management Landscape
4.8. FDA Regulatory Framework for Retinal Imaging and Autonomous AI
4.9. CMS Reimbursement and Coding Landscape
4.10. Commercial Payer and Value-Based Care Environment
4.11. ADA and Clinical Screening Guideline Impact
4.12. HEDIS and Quality-Measure Environment
4.13. HIPAA, Cybersecurity and Clinical Data Governance
4.14. Import/Export Restrictions & Tariff Impact
4.15. Government Diabetes and Vision Health Initiatives
4.16. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.17. Hospital and IDN Value Analysis Committee Decision Framework

What this section provides: This section evaluates the external operating environment surrounding diabetic retinopathy screening devices, including FDA regulation, reimbursement, AI governance, pricing, quality measures, data interoperability, supply chains and institutional procurement requirements.

5. U.S. Diabetic Retinopathy Screening Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
5.2. Non-Mydriatic Fundus Cameras
5.2.1. Automated Tabletop Fundus Cameras
5.2.2. Conventional Non-Mydriatic Digital Cameras
5.2.3. AI-Compatible Fundus Cameras
5.3. AI-Enabled Diabetic Retinopathy Screening Systems
5.3.1. Autonomous AI Diagnostic Platforms
5.3.2. AI-Integrated Camera Systems
5.3.3. Cloud-Based AI Screening Software
5.3.4. AI-Assisted Image Quality Assessment
5.4. Optical Coherence Tomography & OCT Angiography Systems
5.4.1. Spectral-Domain OCT
5.4.2. Swept-Source OCT
5.4.3. OCT Angiography
5.4.4. AI-Assisted OCT Interpretation
5.5. Ultra-Widefield & Multimodal Retinal Imaging Systems
5.5.1. Ultra-Widefield Fundus Imaging
5.5.2. Scanning Laser Ophthalmoscopy
5.5.3. Multimodal Retinal Imaging Platforms
5.6. Portable & Smartphone-Connected Screening Systems
5.6.1. Handheld Fundus Cameras
5.6.2. Smartphone-Connected Retinal Imaging
5.6.3. Portable Autonomous AI Systems
5.6.4. Mobile Screening Equipment

What this section provides: This section identifies the product categories generating current screening-device revenue and evaluates which hardware, software and AI-integrated platforms are positioned to capture the strongest growth through 2035.

6. U.S. Diabetic Retinopathy Screening Devices Market – By Device Modality

6.1. Overview
6.1.1. Segment Share Analysis, By Device Modality, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Device Modality, 2021–2035 (US$ Billion)
6.2. Tabletop & Desktop Systems
6.2.1. Fully Automated Systems
6.2.2. Technician-Operated Systems
6.2.3. Fixed Specialist Imaging Platforms
6.3. Handheld Systems
6.3.1. Non-Mydriatic Handheld Cameras
6.3.2. AI-Enabled Handheld Cameras
6.3.3. Wireless and Cloud-Connected Handheld Systems
6.4. Smartphone-Connected Systems
6.4.1. Smartphone Fundus Adapters
6.4.2. Integrated Smartphone Retinal Cameras
6.4.3. Smartphone AI Screening Platforms
6.5. Mobile & Distributed Screening Configurations
6.5.1. Mobile Screening Vans
6.5.2. Rotating Multi-Site Screening Programs
6.5.3. Community Outreach Screening Systems
6.5.4. Remote and Rural Screening Deployments

What this section provides: This section evaluates how form factor, portability, automation and infrastructure requirements influence device adoption across high-volume specialist sites, primary care, community health and geographically dispersed screening programs.

7. U.S. Diabetic Retinopathy Screening Devices Market – By Screening Approach

7.1. Overview
7.1.1. Segment Share Analysis, By Screening Approach, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By Screening Approach, 2021–2035 (US$ Billion)
7.2. Autonomous AI Point-of-Care Screening
7.2.1. Primary Care Autonomous Screening
7.2.2. Endocrinology-Based Autonomous Screening
7.2.3. Community Health Autonomous Screening
7.2.4. Retail and Distributed Autonomous Screening
7.3. Teleophthalmology & Remote Human Grading
7.3.1. Ophthalmologist Remote Interpretation
7.3.2. Optometrist Remote Interpretation
7.3.3. Centralized Reading Centers
7.3.4. Health System Tele-Retina Networks
7.4. Specialist-Led Digital Screening
7.4.1. Ophthalmology-Based Screening
7.4.2. Retina Specialist Screening
7.4.3. Optometry-Based Screening
7.5. AI-Assisted Specialist Triage
7.5.1. AI Image Prioritization
7.5.2. AI-Assisted Disease Grading
7.5.3. Human-in-the-Loop Screening Workflows
7.5.4. Referral Prioritization and Risk Stratification

What this section provides: This section compares the principal U.S. diabetic retinopathy screening delivery models and shows how autonomous diagnosis, teleophthalmology and specialist-supported screening differ in scalability, economics and clinical workflow.

8. U.S. Diabetic Retinopathy Screening Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
8.2. Ophthalmology, Retina & Optometry Practices
8.2.1. Ophthalmology Practices
8.2.2. Retina Specialty Practices
8.2.3. Optometry Practices
8.3. Primary Care & Endocrinology Practices
8.3.1. Primary Care Practices
8.3.2. Endocrinology and Diabetes Centers
8.3.3. Multispecialty Physician Groups
8.4. Hospitals & Integrated Delivery Networks
8.4.1. Academic Medical Centers
8.4.2. Community Hospitals
8.4.3. Integrated Delivery Networks
8.4.4. Hospital-Owned Ambulatory Clinics
8.5. Federally Qualified Health Centers & Community Care
8.5.1. Federally Qualified Health Centers
8.5.2. Rural Health Clinics
8.5.3. Community Health Organizations
8.5.4. Safety-Net Providers
8.6. Payers, Retail, Mobile & Population Health Programs
8.6.1. Health Plan Screening Programs
8.6.2. Accountable Care Organizations
8.6.3. Retail Health Clinics
8.6.4. Mobile Screening Providers
8.6.5. Employer and Population Health Programs

What this section provides: This section identifies the customer groups expected to drive equipment purchasing, AI subscriptions, screening volumes and distributed deployment, with particular attention to the movement of diabetic eye screening into primary care.

9. U.S. Diabetic Retinopathy Screening Devices Market: Screening Program Economics & Procurement Analysis

9.1. Overview
9.2. Capital Purchase Model
9.3. Equipment-as-a-Service Model
9.4. Subscription-Based AI Model
9.5. Per-Examination AI Pricing Model
9.6. Enterprise Health System Contracting
9.7. Group Purchasing Organization Influence
9.8. Distributor and Specialty Channel Model
9.9. Primary Care Practice Procurement Economics
9.10. FQHC and Community Health Procurement Economics
9.11. Payer-Funded Screening Programs
9.12. Cost per Screened Patient Analysis
9.13. Cost per Diagnosed Case Analysis
9.14. Screening Throughput and Staff Productivity Analysis
9.15. Reimbursement Capture and ROI Analysis
9.16. Quality Measure and Care-Gap Closure Economics
9.17. Referral Conversion Economics
9.18. Procurement Decision-Making Framework

What this section provides: This section examines how diabetic retinopathy screening technologies are financed, purchased and economically justified across U.S. care settings without creating an additional formal market segmentation.

10. U.S. Diabetic Retinopathy Screening Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diabetes Population Analysis
10.1.4. Regional Diabetic Retinopathy Burden Analysis
10.1.5. Regional Screening Compliance and Care-Gap Analysis
10.1.6. Regional Ophthalmologist and Optometrist Access Analysis
10.1.7. Regional Primary Care and Endocrinology Infrastructure
10.1.8. Regional AI and Teleophthalmology Adoption
10.1.9. Regional Reimbursement and Procurement Dynamics
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers, AI Vendors and Screening Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035
10.2.5. West Region Market Size and Forecast, By Device Modality, 2021–2035
10.2.6. West Region Market Size and Forecast, By Screening Approach, 2021–2035
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035
10.2.8. West Region Screening Procurement & Deployment Analysis
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035
10.2.9.3. California Market Size and Forecast, By Device Modality, 2021–2035
10.2.9.4. California Market Size and Forecast, By Screening Approach, 2021–2035
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035
10.2.9.6. California Screening Procurement & Deployment Outlook
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035
10.2.10.3. Washington Market Size and Forecast, By Device Modality, 2021–2035
10.2.10.4. Washington Market Size and Forecast, By Screening Approach, 2021–2035
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035
10.2.10.6. Washington Screening Procurement & Deployment Outlook
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035
10.2.11.3. Arizona Market Size and Forecast, By Device Modality, 2021–2035
10.2.11.4. Arizona Market Size and Forecast, By Screening Approach, 2021–2035
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035
10.2.11.6. Arizona Screening Procurement & Deployment Outlook
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035
10.2.12.3. Colorado Market Size and Forecast, By Device Modality, 2021–2035
10.2.12.4. Colorado Market Size and Forecast, By Screening Approach, 2021–2035
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035
10.2.12.6. Colorado Screening Procurement & Deployment Outlook
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035
10.2.13.3. Oregon Market Size and Forecast, By Device Modality, 2021–2035
10.2.13.4. Oregon Market Size and Forecast, By Screening Approach, 2021–2035
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035
10.2.13.6. Oregon Screening Procurement & Deployment Outlook
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035
10.2.14.3. Utah Market Size and Forecast, By Device Modality, 2021–2035
10.2.14.4. Utah Market Size and Forecast, By Screening Approach, 2021–2035
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035
10.2.14.6. Utah Screening Procurement & Deployment Outlook
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035
10.2.15.3. Nevada Market Size and Forecast, By Device Modality, 2021–2035
10.2.15.4. Nevada Market Size and Forecast, By Screening Approach, 2021–2035
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035
10.2.15.6. Nevada Screening Procurement & Deployment Outlook
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035
10.2.16.3. New Mexico Market Size and Forecast, By Device Modality, 2021–2035
10.2.16.4. New Mexico Market Size and Forecast, By Screening Approach, 2021–2035
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035
10.2.16.6. New Mexico Screening Procurement & Deployment Outlook
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035
10.2.17.3. Idaho Market Size and Forecast, By Device Modality, 2021–2035
10.2.17.4. Idaho Market Size and Forecast, By Screening Approach, 2021–2035
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035
10.2.17.6. Idaho Screening Procurement & Deployment Outlook
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035
10.2.18.3. Montana Market Size and Forecast, By Device Modality, 2021–2035
10.2.18.4. Montana Market Size and Forecast, By Screening Approach, 2021–2035
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035
10.2.18.6. Montana Screening Procurement & Deployment Outlook
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035
10.2.19.3. Wyoming Market Size and Forecast, By Device Modality, 2021–2035
10.2.19.4. Wyoming Market Size and Forecast, By Screening Approach, 2021–2035
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035
10.2.19.6. Wyoming Screening Procurement & Deployment Outlook
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035
10.2.20.3. Alaska Market Size and Forecast, By Device Modality, 2021–2035
10.2.20.4. Alaska Market Size and Forecast, By Screening Approach, 2021–2035
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035
10.2.20.6. Alaska Screening Procurement & Deployment Outlook
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035
10.2.21.3. Hawaii Market Size and Forecast, By Device Modality, 2021–2035
10.2.21.4. Hawaii Market Size and Forecast, By Screening Approach, 2021–2035
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035
10.2.21.6. Hawaii Screening Procurement & Deployment Outlook
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers, AI Vendors and Screening Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035
10.3.5. Northeast Region Market Size and Forecast, By Device Modality, 2021–2035
10.3.6. Northeast Region Market Size and Forecast, By Screening Approach, 2021–2035
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035
10.3.8. Northeast Region Screening Procurement & Deployment Analysis
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.9.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.9.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.9.5. Market Size and Forecast, By End User, 2021–2035
10.3.9.6. Screening Procurement & Deployment Outlook
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.10.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.10.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.10.5. Market Size and Forecast, By End User, 2021–2035
10.3.10.6. Screening Procurement & Deployment Outlook
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.11.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.11.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.11.5. Market Size and Forecast, By End User, 2021–2035
10.3.11.6. Screening Procurement & Deployment Outlook
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.12.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.12.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.12.5. Market Size and Forecast, By End User, 2021–2035
10.3.12.6. Screening Procurement & Deployment Outlook
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.13.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.13.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.13.5. Market Size and Forecast, By End User, 2021–2035
10.3.13.6. Screening Procurement & Deployment Outlook
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.14.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.14.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.14.5. Market Size and Forecast, By End User, 2021–2035
10.3.14.6. Screening Procurement & Deployment Outlook
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.15.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.15.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.15.5. Market Size and Forecast, By End User, 2021–2035
10.3.15.6. Screening Procurement & Deployment Outlook
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.16.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.16.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.16.5. Market Size and Forecast, By End User, 2021–2035
10.3.16.6. Screening Procurement & Deployment Outlook
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.17.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.17.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.17.5. Market Size and Forecast, By End User, 2021–2035
10.3.17.6. Screening Procurement & Deployment Outlook
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Market Size and Forecast, By Product Type, 2021–2035
10.3.18.3. Market Size and Forecast, By Device Modality, 2021–2035
10.3.18.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.3.18.5. Market Size and Forecast, By End User, 2021–2035
10.3.18.6. Screening Procurement & Deployment Outlook
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers, AI Vendors and Screening Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035
10.4.5. South Region Market Size and Forecast, By Device Modality, 2021–2035
10.4.6. South Region Market Size and Forecast, By Screening Approach, 2021–2035
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035
10.4.8. South Region Screening Procurement & Deployment Analysis
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.9.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.9.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.9.5. Market Size and Forecast, By End User, 2021–2035
10.4.9.6. Screening Procurement & Deployment Outlook
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.10.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.10.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.10.5. Market Size and Forecast, By End User, 2021–2035
10.4.10.6. Screening Procurement & Deployment Outlook
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.11.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.11.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.11.5. Market Size and Forecast, By End User, 2021–2035
10.4.11.6. Screening Procurement & Deployment Outlook
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.12.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.12.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.12.5. Market Size and Forecast, By End User, 2021–2035
10.4.12.6. Screening Procurement & Deployment Outlook
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.13.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.13.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.13.5. Market Size and Forecast, By End User, 2021–2035
10.4.13.6. Screening Procurement & Deployment Outlook
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.14.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.14.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.14.5. Market Size and Forecast, By End User, 2021–2035
10.4.14.6. Screening Procurement & Deployment Outlook
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.15.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.15.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.15.5. Market Size and Forecast, By End User, 2021–2035
10.4.15.6. Screening Procurement & Deployment Outlook
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.16.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.16.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.16.5. Market Size and Forecast, By End User, 2021–2035
10.4.16.6. Screening Procurement & Deployment Outlook
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.17.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.17.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.17.5. Market Size and Forecast, By End User, 2021–2035
10.4.17.6. Screening Procurement & Deployment Outlook
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.18.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.18.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.18.5. Market Size and Forecast, By End User, 2021–2035
10.4.18.6. Screening Procurement & Deployment Outlook
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.19.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.19.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.19.5. Market Size and Forecast, By End User, 2021–2035
10.4.19.6. Screening Procurement & Deployment Outlook
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.20.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.20.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.20.5. Market Size and Forecast, By End User, 2021–2035
10.4.20.6. Screening Procurement & Deployment Outlook
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.21.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.21.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.21.5. Market Size and Forecast, By End User, 2021–2035
10.4.21.6. Screening Procurement & Deployment Outlook
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.22.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.22.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.22.5. Market Size and Forecast, By End User, 2021–2035
10.4.22.6. Screening Procurement & Deployment Outlook
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. Market Size and Forecast, By Product Type, 2021–2035
10.4.23.3. Market Size and Forecast, By Device Modality, 2021–2035
10.4.23.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.4.23.5. Market Size and Forecast, By End User, 2021–2035
10.4.23.6. Screening Procurement & Deployment Outlook
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers, AI Vendors and Screening Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035
10.5.5. Midwest Region Market Size and Forecast, By Device Modality, 2021–2035
10.5.6. Midwest Region Market Size and Forecast, By Screening Approach, 2021–2035
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035
10.5.8. Midwest Region Screening Procurement & Deployment Analysis
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.9.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.9.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.9.5. Market Size and Forecast, By End User, 2021–2035
10.5.9.6. Screening Procurement & Deployment Outlook
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.10.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.10.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.10.5. Market Size and Forecast, By End User, 2021–2035
10.5.10.6. Screening Procurement & Deployment Outlook
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.11.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.11.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.11.5. Market Size and Forecast, By End User, 2021–2035
10.5.11.6. Screening Procurement & Deployment Outlook
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.12.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.12.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.12.5. Market Size and Forecast, By End User, 2021–2035
10.5.12.6. Screening Procurement & Deployment Outlook
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.13.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.13.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.13.5. Market Size and Forecast, By End User, 2021–2035
10.5.13.6. Screening Procurement & Deployment Outlook
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.14.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.14.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.14.5. Market Size and Forecast, By End User, 2021–2035
10.5.14.6. Screening Procurement & Deployment Outlook
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.15.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.15.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.15.5. Market Size and Forecast, By End User, 2021–2035
10.5.15.6. Screening Procurement & Deployment Outlook
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.16.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.16.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.16.5. Market Size and Forecast, By End User, 2021–2035
10.5.16.6. Screening Procurement & Deployment Outlook
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.17.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.17.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.17.5. Market Size and Forecast, By End User, 2021–2035
10.5.17.6. Screening Procurement & Deployment Outlook
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.18.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.18.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.18.5. Market Size and Forecast, By End User, 2021–2035
10.5.18.6. Screening Procurement & Deployment Outlook
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.19.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.19.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.19.5. Market Size and Forecast, By End User, 2021–2035
10.5.19.6. Screening Procurement & Deployment Outlook
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. Market Size and Forecast, By Product Type, 2021–2035
10.5.20.3. Market Size and Forecast, By Device Modality, 2021–2035
10.5.20.4. Market Size and Forecast, By Screening Approach, 2021–2035
10.5.20.5. Market Size and Forecast, By End User, 2021–2035
10.5.20.6. Screening Procurement & Deployment Outlook

What this section provides: This section delivers detailed four-region and 50-state intelligence covering market size, diabetes and DR burden, screening-access gaps, AI and teleophthalmology adoption, customer infrastructure, procurement behavior and state-level commercial opportunities.

11. U.S. Diabetic Retinopathy Screening Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. AI & Digital Innovators
11.3.4. Emerging Players
11.4. Competitive Analysis by Retinal Imaging Hardware
11.5. Competitive Analysis by Autonomous AI Platform
11.6. Competitive Analysis by Portable Screening Capability
11.7. Competitive Analysis by Teleophthalmology Capability
11.8. Partnership, Distribution and Integration Analysis
11.9. Company Profiles
11.9.1. Topcon Healthcare
11.9.2. Digital Diagnostics
11.9.3. Eyenuk, Inc.
11.9.4. AEYE Health
11.9.5. Optomed Plc
11.9.6. Carl Zeiss Meditec AG
11.9.7. Canon U.S.A., Inc.
11.9.8. NIDEK CO., LTD.
11.9.9. Heidelberg Engineering
11.9.10. Kowa American Corporation
11.9.11. Optos / Nikon Corporation
11.9.12. Revenio Group / iCare
11.9.13. CenterVue
11.9.14. Baxter / Welch Allyn
11.9.15. Visionix
11.9.16. Remidio Innovative Solutions
11.9.17. Forus Health
11.9.18. EyePACS
11.9.19. VisionQuest Biomedical
11.9.20. RetinAI Medical AG
11.9.21. Altris AI
11.9.22. Volk Optical
11.9.23. Phoenix Technology Group
11.9.24. Tomey Corporation
11.9.25. OCULUS Optikgeräte GmbH

Note: Each company profile will include company overview, diabetic retinopathy screening portfolio, retinal imaging capabilities, AI positioning, U.S. market strategy, regulatory status, distribution model, partnerships, clinical evidence, product launches and recent developments.

What this section provides: This section gives clients competitor benchmarking, platform positioning, AI-versus-hardware competitive intelligence, product portfolio visibility, innovation direction, partnership activity and strategic insight into companies participating in the U.S. diabetic retinopathy screening ecosystem.

12. U.S. Diabetic Retinopathy Screening Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Autonomous Artificial Intelligence
12.2.2. Handheld AI-Enabled Fundus Imaging
12.2.3. Robotic and Automated Image Acquisition
12.2.4. Ultra-Widefield Retinal Imaging
12.2.5. AI-Assisted OCT and Multimodal Imaging
12.2.6. Smartphone-Based Retinal Screening
12.2.7. Cloud-Based Screening and Referral Platforms
12.3. Future of Primary Care-Based Retinal Screening
12.4. Future of Teleophthalmology and Distributed Care
12.5. Evolution of Autonomous AI Reimbursement
12.6. Emerging Business Models
12.7. Expansion of Screening-as-a-Service
12.8. Business Opportunities for Startups and Existing Players
12.9. Investment Prioritization Matrix
12.10. High-Growth State Opportunity Matrix
12.11. Technology Adoption Outlook Through 2035

What this section provides: This section prepares clients for future technology disruption, autonomous AI penetration, evolving reimbursement, primary-care decentralization, changing business models, investment opportunities and potential adoption scenarios through 2035.

13. U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations

13.1. Recommendations for Retinal Imaging Device Manufacturers
13.2. Recommendations for Autonomous AI Developers
13.3. Recommendations for Hospitals and Integrated Delivery Networks
13.4. Recommendations for Primary Care and Endocrinology Networks
13.5. Recommendations for Ophthalmology and Retina Providers
13.6. Recommendations for Health Plans and Accountable Care Organizations
13.7. Recommendations for FQHCs and Community Health Organizations
13.8. Recommendations for Investors and Private Equity Firms
13.9. Recommendations for Distributors and Channel Partners
13.10. Recommendations for New Entrants and Startups
13.11. U.S. Go-to-Market Strategy Considerations
13.12. Product Positioning and Portfolio Expansion Guidance
13.13. Autonomous AI Commercialization Strategy
13.14. Enterprise IDN Contracting Strategy
13.15. Rural and Underserved Market Expansion Strategy
13.16. Reimbursement and Health Economic Evidence Strategy
13.17. EHR Integration and Clinical Workflow Strategy

What this section provides: This section converts market intelligence into actionable strategic recommendations for product development, AI commercialization, reimbursement planning, account targeting, state prioritization, distribution, enterprise contracting and competitive differentiation.

14. U.S. Diabetic Retinopathy Screening Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition Limitation
14.3. Data Use Limitation
14.4. Forecasting Limitation
14.5. State-Level Estimation Limitation
14.6. AI and Regulatory Status Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer

What this section provides: This section clarifies report scope, market-model boundaries, state-level estimation methodology, forecast limitations, regulatory considerations, legal boundaries and data-use terms.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Diabetic Retinopathy Screening Devices Market: Market Definition and Scope
TABLE 3: U.S. Diabetic Retinopathy Screening Devices Market: Research Methodology Framework
TABLE 4: U.S. Diabetic Retinopathy Screening Devices Market: Key Assumptions
TABLE 5: U.S. Diabetic Retinopathy Screening Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Diabetic Retinopathy Screening Devices Market: Stakeholder Analysis
TABLE 7: U.S. Diabetic Retinopathy Screening Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Diabetic Retinopathy Screening Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Diabetic Retinopathy Screening Devices Market: Market Attractiveness Index
TABLE 10: U.S. Diabetic Retinopathy Screening Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Diabetic Retinopathy Screening Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Diabetic Retinopathy Screening Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Diabetic Retinopathy Screening Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Diabetic Retinopathy Screening Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Diabetic Retinopathy Screening Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Diabetic Retinopathy Screening Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Diabetic Retinopathy Screening Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Diabetic Retinopathy Screening Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Diabetic Retinopathy Screening Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Diabetic Retinopathy Screening Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Diabetic Retinopathy Screening Devices Market: Screening Cost per Completed Examination Analysis
TABLE 22: U.S. Diabetic Retinopathy Screening Devices Market: Specialist Capacity and Referral Economics
TABLE 23: U.S. Diabetic Retinopathy Screening Devices Market: Health System Capital Procurement Behavior Matrix
TABLE 24: U.S. Diabetic Retinopathy Screening Devices Market: Screening Completion and Patient Drop-Off Analysis
TABLE 25: U.S. Diabetic Retinopathy Screening Devices Market: PESTEL Analysis
TABLE 26: U.S. Diabetic Retinopathy Screening Devices Market: Porter’s Five Forces Analysis
TABLE 27: U.S. Diabetic Retinopathy Screening Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 28: U.S. Diabetic Retinopathy Screening Devices Market: Value Chain Analysis
TABLE 29: U.S. Diabetic Retinopathy Screening Devices Market: Supply Chain Analysis
TABLE 30: U.S. Diabetic Retinopathy Screening Devices Market: Retinal Imaging Manufacturing Ecosystem
TABLE 31: U.S. Diabetic Retinopathy Screening Devices Market: AI and Digitalization Impact
TABLE 32: U.S. Diabetic Retinopathy Screening Devices Market: Cloud-Based Retinal Image Management Landscape
TABLE 33: U.S. Diabetic Retinopathy Screening Devices Market: FDA Regulatory Framework Analysis
TABLE 34: U.S. Diabetic Retinopathy Screening Devices Market: CMS Reimbursement and Coding Landscape
TABLE 35: U.S. Diabetic Retinopathy Screening Devices Market: Commercial Payer and Value-Based Care Landscape
TABLE 36: U.S. Diabetic Retinopathy Screening Devices Market: Clinical Guideline Impact Analysis
TABLE 37: U.S. Diabetic Retinopathy Screening Devices Market: HEDIS and Quality-Measure Environment
TABLE 38: U.S. Diabetic Retinopathy Screening Devices Market: HIPAA, Cybersecurity and Data Governance Analysis
TABLE 39: U.S. Diabetic Retinopathy Screening Devices Market: Government Initiatives and Public Health Programs
TABLE 40: U.S. Diabetic Retinopathy Screening Devices Market: Hospital and IDN Value Analysis Decision Framework
TABLE 41: U.S. Diabetic Retinopathy Screening Devices Market: Product Type Snapshot, 2025
TABLE 42: Segment Dashboard; Definition and Scope, by Product Type
TABLE 43: U.S. Diabetic Retinopathy Screening Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 44: U.S. Diabetic Retinopathy Screening Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 45: Non-Mydriatic Fundus Cameras Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: AI-Enabled Diabetic Retinopathy Screening Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: OCT & OCT Angiography Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Ultra-Widefield & Multimodal Retinal Imaging Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: Portable & Smartphone-Connected Screening Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Diabetic Retinopathy Screening Devices Market: Device Modality Snapshot, 2025
TABLE 51: Segment Dashboard; Definition and Scope, by Device Modality
TABLE 52: U.S. Diabetic Retinopathy Screening Devices Market, by Device Modality, 2021–2035 (US$ Billion)
TABLE 53: U.S. Diabetic Retinopathy Screening Devices Market: Segment Share Analysis, by Device Modality, 2025 & 2035 (%)
TABLE 54: Tabletop & Desktop Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: Handheld Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: Smartphone-Connected Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Mobile & Distributed Screening Configurations Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Diabetic Retinopathy Screening Devices Market: Screening Approach Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by Screening Approach
TABLE 60: U.S. Diabetic Retinopathy Screening Devices Market, by Screening Approach, 2021–2035 (US$ Billion)
TABLE 61: U.S. Diabetic Retinopathy Screening Devices Market: Segment Share Analysis, by Screening Approach, 2025 & 2035 (%)
TABLE 62: Autonomous AI Point-of-Care Screening Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Teleophthalmology & Remote Human Grading Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: Specialist-Led Digital Screening Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: AI-Assisted Specialist Triage Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Diabetic Retinopathy Screening Devices Market: End User Snapshot, 2025
TABLE 67: Segment Dashboard; Definition and Scope, by End User
TABLE 68: U.S. Diabetic Retinopathy Screening Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 69: U.S. Diabetic Retinopathy Screening Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 70: Ophthalmology, Retina & Optometry Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Primary Care & Endocrinology Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Hospitals & Integrated Delivery Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: FQHCs & Community Care Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: Payers, Retail, Mobile & Population Health Programs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Diabetic Retinopathy Screening Devices Market: Screening Program Economics Snapshot, 2025
TABLE 76: Capital Purchase vs. Equipment-as-a-Service Model Comparison
TABLE 77: Subscription-Based vs. Per-Examination AI Pricing Analysis
TABLE 78: Enterprise Health System and IDN Contracting Matrix
TABLE 79: Primary Care and FQHC Procurement Economics
TABLE 80: Screening Throughput and Staff Productivity Analysis
TABLE 81: Reimbursement Capture and Screening ROI Analysis
TABLE 82: Quality Measure and Care-Gap Closure Economics
TABLE 83: Referral Conversion Economics and Procurement Decision Framework
TABLE 84: U.S. Diabetic Retinopathy Screening Devices Market: Regional Snapshot, 2025
TABLE 85: Segment Dashboard; Definition and Scope, by Geography
TABLE 86: U.S. Diabetic Retinopathy Screening Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 87: U.S. Diabetic Retinopathy Screening Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 88: U.S. Diabetic Retinopathy Screening Devices Market: Regional Diabetes and DR Burden Analysis
TABLE 89: U.S. Diabetic Retinopathy Screening Devices Market: Regional Screening Compliance and Access Analysis
TABLE 90: West Region U.S. Diabetic Retinopathy Screening Devices Market: Regional Overview and Trends
TABLE 91: West Region U.S. Diabetic Retinopathy Screening Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Diabetic Retinopathy Screening Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Diabetic Retinopathy Screening Devices Market, by Screening Approach, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Diabetic Retinopathy Screening Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 95: California Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Washington Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Arizona Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Colorado Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Oregon Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Utah Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Nevada Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: New Mexico Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Idaho Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Montana Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Wyoming Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Alaska Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Hawaii Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Northeast Region U.S. Diabetic Retinopathy Screening Devices Market: Regional Overview and Trends
TABLE 109: Northeast Region U.S. Diabetic Retinopathy Screening Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 110: Northeast Region U.S. Diabetic Retinopathy Screening Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 111: Northeast Region U.S. Diabetic Retinopathy Screening Devices Market, by Screening Approach, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Diabetic Retinopathy Screening Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: New York Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Massachusetts Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: New Jersey Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Pennsylvania Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Connecticut Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Maine Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Vermont Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: New Hampshire Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Rhode Island Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Delaware Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: South Region U.S. Diabetic Retinopathy Screening Devices Market: Regional Overview and Trends
TABLE 124: South Region U.S. Diabetic Retinopathy Screening Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 125: South Region U.S. Diabetic Retinopathy Screening Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Diabetic Retinopathy Screening Devices Market, by Screening Approach, 2021–2035 (US$ Billion)
TABLE 127: South Region U.S. Diabetic Retinopathy Screening Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: Texas Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Florida Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Georgia Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: North Carolina Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Tennessee Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: South Carolina Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Alabama Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Mississippi Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Louisiana Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Arkansas Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Kentucky Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Oklahoma Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Virginia Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Maryland Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: West Virginia Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Midwest Region U.S. Diabetic Retinopathy Screening Devices Market: Regional Overview and Trends
TABLE 144: Midwest Region U.S. Diabetic Retinopathy Screening Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 145: Midwest Region U.S. Diabetic Retinopathy Screening Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 146: Midwest Region U.S. Diabetic Retinopathy Screening Devices Market, by Screening Approach, 2021–2035 (US$ Billion)
TABLE 147: Midwest Region U.S. Diabetic Retinopathy Screening Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Illinois Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Ohio Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Michigan Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Minnesota Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Indiana Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Wisconsin Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Missouri Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Iowa Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Kansas Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Nebraska Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: North Dakota Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: South Dakota Diabetic Retinopathy Screening Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: U.S. Diabetic Retinopathy Screening Devices Market: Competitive Landscape Snapshot, 2025
TABLE 161: U.S. Diabetic Retinopathy Screening Devices Market: Key Company Market Share Analysis, 2025
TABLE 162: U.S. Diabetic Retinopathy Screening Devices Market: Company Positioning Matrix
TABLE 163: U.S. Diabetic Retinopathy Screening Devices Market: Retinal Imaging Hardware Benchmarking
TABLE 164: U.S. Diabetic Retinopathy Screening Devices Market: Autonomous AI Platform Benchmarking
TABLE 165: U.S. Diabetic Retinopathy Screening Devices Market: Portable Screening Capability Benchmarking
TABLE 166: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Developments, Partnerships and Product Launches
TABLE 167: Topcon Healthcare: Company Profile
TABLE 168: Digital Diagnostics: Company Profile
TABLE 169: Eyenuk, Inc.: Company Profile
TABLE 170: AEYE Health: Company Profile
TABLE 171: Optomed Plc: Company Profile
TABLE 172: Carl Zeiss Meditec AG: Company Profile
TABLE 173: Canon U.S.A., Inc.: Company Profile
TABLE 174: NIDEK CO., LTD.: Company Profile
TABLE 175: Heidelberg Engineering: Company Profile
TABLE 176: Kowa American Corporation: Company Profile
TABLE 177: Optos / Nikon Corporation: Company Profile
TABLE 178: Revenio Group / iCare: Company Profile
TABLE 179: CenterVue: Company Profile
TABLE 180: Baxter / Welch Allyn: Company Profile
TABLE 181: Visionix: Company Profile
TABLE 182: Remidio Innovative Solutions: Company Profile
TABLE 183: Forus Health: Company Profile
TABLE 184: EyePACS: Company Profile
TABLE 185: VisionQuest Biomedical: Company Profile
TABLE 186: RetinAI Medical AG: Company Profile
TABLE 187: Altris AI: Company Profile
TABLE 188: Volk Optical: Company Profile
TABLE 189: Phoenix Technology Group: Company Profile
TABLE 190: Tomey Corporation: Company Profile
TABLE 191: OCULUS Optikgeräte GmbH: Company Profile
TABLE 192: U.S. Diabetic Retinopathy Screening Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 193: U.S. Diabetic Retinopathy Screening Devices Market: Disruptive Technologies Impact Matrix
TABLE 194: U.S. Diabetic Retinopathy Screening Devices Market: Autonomous AI Adoption Outlook
TABLE 195: U.S. Diabetic Retinopathy Screening Devices Market: Primary Care Screening Expansion Outlook
TABLE 196: U.S. Diabetic Retinopathy Screening Devices Market: Emerging Business Models
TABLE 197: U.S. Diabetic Retinopathy Screening Devices Market: High-Growth State Opportunity Matrix
TABLE 198: U.S. Diabetic Retinopathy Screening Devices Market: Investment Prioritization Matrix
TABLE 199: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations for Retinal Imaging Manufacturers
TABLE 200: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations for Autonomous AI Developers
TABLE 201: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations for Hospitals and IDNs
TABLE 202: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations for Primary Care and Endocrinology Networks
TABLE 203: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations for Health Plans and ACOs
TABLE 204: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 205: U.S. Diabetic Retinopathy Screening Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 206: U.S. Diabetic Retinopathy Screening Devices Market: Go-to-Market Strategy Considerations
TABLE 207: U.S. Diabetic Retinopathy Screening Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 208: U.S. Diabetic Retinopathy Screening Devices Market: Reimbursement and Health Economic Evidence Strategy
TABLE 209: U.S. Diabetic Retinopathy Screening Devices Market: EHR Integration and Clinical Workflow Strategy
TABLE 210: U.S. Diabetic Retinopathy Screening Devices Market: Scope Limitation
TABLE 211: U.S. Diabetic Retinopathy Screening Devices Market: Market Definition Limitation
TABLE 212: U.S. Diabetic Retinopathy Screening Devices Market: Data Use Limitation
TABLE 213: U.S. Diabetic Retinopathy Screening Devices Market: Forecasting and State-Level Estimation Limitation
TABLE 214: U.S. Diabetic Retinopathy Screening Devices Market: AI and Regulatory Status Limitation
TABLE 215: U.S. Diabetic Retinopathy Screening Devices Market: Legal and Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Diabetic Retinopathy Screening Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Diabetic Retinopathy Screening Devices Market Ecosystem
FIGURE 4: Stakeholder Ecosystem Analysis
FIGURE 5: U.S. Diabetic Retinopathy Screening Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Diabetic Retinopathy Screening Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Diabetic Retinopathy Screening Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: High-Growth Opportunity Map
FIGURE 10: U.S. Diabetes Population and Diabetic Retinopathy Screening Opportunity Framework
FIGURE 11: Market Dynamics
FIGURE 12: Innovation & Patent Landscape, 2021–2025
FIGURE 13: Clinical Workflow Economics Framework
FIGURE 14: Diabetic Retinopathy Screening Patient Journey and Drop-Off Framework
FIGURE 15: Health System Procurement Decision Framework
FIGURE 16: PESTEL Analysis
FIGURE 17: Porter’s Five Forces Analysis
FIGURE 18: Value Chain Analysis
FIGURE 19: Supply Chain Analysis
FIGURE 20: FDA Regulatory and Reimbursement Framework
FIGURE 21: Autonomous AI and Digital Screening Technology Landscape
FIGURE 22: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Non-Mydriatic Fundus Cameras Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: AI-Enabled Diabetic Retinopathy Screening Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: OCT & OCT Angiography Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Ultra-Widefield & Multimodal Retinal Imaging Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Portable & Smartphone-Connected Screening Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Device Modality Segment Market Share Analysis, 2025 & 2035
FIGURE 30: Device Modality Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Tabletop & Desktop Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Handheld Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Smartphone-Connected Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Mobile & Distributed Screening Configurations Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Screening Approach Segment Market Share Analysis, 2025 & 2035
FIGURE 36: Screening Approach Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Autonomous AI Point-of-Care Screening Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Teleophthalmology & Remote Human Grading Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Specialist-Led Digital Screening Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: AI-Assisted Specialist Triage Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 42: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Ophthalmology, Retina & Optometry Practices Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 44: Primary Care & Endocrinology Practices Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 45: Hospitals & Integrated Delivery Networks Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 46: FQHCs & Community Care Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 47: Payers, Retail, Mobile & Population Health Programs Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 48: Screening Program Economics Framework
FIGURE 49: Capital Purchase vs. Subscription and Per-Exam Revenue Model
FIGURE 50: Screening Throughput, Reimbursement and ROI Framework
FIGURE 51: Quality-Gap Closure and Referral Conversion Framework
FIGURE 52: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: U.S. Diabetic Retinopathy Screening Devices Market: State-Level Opportunity Map
FIGURE 55: U.S. Diabetes and Diabetic Retinopathy Burden by Region
FIGURE 56: West Region Market Share Analysis by State, 2025
FIGURE 57: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: California Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 59: Washington Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 60: Arizona Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 61: Colorado Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 62: Oregon Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 63: Utah Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 64: Nevada Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: New Mexico Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Idaho Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: Montana Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: Wyoming Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: Alaska Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Hawaii Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: Northeast Region Market Share Analysis by State, 2025
FIGURE 72: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New York Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Massachusetts Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 75: New Jersey Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 76: Pennsylvania Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 77: Connecticut Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 78: Maine Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: Vermont Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 80: New Hampshire Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 81: Rhode Island Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 82: Delaware Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: South Region Market Share Analysis by State, 2025
FIGURE 84: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Texas Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: Florida Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: Georgia Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 88: North Carolina Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 89: Tennessee Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 90: South Carolina Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 91: Alabama Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 92: Mississippi Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: Louisiana Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: Arkansas Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: Kentucky Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: Oklahoma Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: Virginia Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Maryland Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: West Virginia Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: Midwest Region Market Share Analysis by State, 2025
FIGURE 101: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Illinois Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: Ohio Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: Michigan Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Minnesota Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 106: Indiana Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 107: Wisconsin Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 108: Missouri Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 109: Iowa Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: Kansas Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: Nebraska Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: North Dakota Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 113: South Dakota Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 114: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 115: Company Positioning Matrix
FIGURE 116: Retinal Imaging Hardware Competitive Benchmarking
FIGURE 117: Autonomous AI Platform Competitive Benchmarking
FIGURE 118: Key Player Product Portfolio Benchmarking
FIGURE 119: Strategic Developments, Partnerships and Product Launches
FIGURE 120: U.S. Diabetic Retinopathy Screening Technology Innovation Roadmap
FIGURE 121: Autonomous AI Screening Adoption Roadmap, 2026–2035
FIGURE 122: Handheld and Portable Retinal Imaging Opportunity Map
FIGURE 123: Primary Care-Based Retinal Screening Expansion Roadmap
FIGURE 124: Teleophthalmology and Distributed Screening Growth Roadmap
FIGURE 125: Future Market Scenario Analysis, 2026–2035
FIGURE 126: Disruptive Technologies Impact Matrix
FIGURE 127: Emerging Business Model Matrix
FIGURE 128: High-Growth State Opportunity Matrix
FIGURE 129: Investment Prioritization Matrix
FIGURE 130: Strategic Growth Roadmap for U.S. Diabetic Retinopathy Screening Device Companies
FIGURE 131: Go-to-Market Strategy Framework
FIGURE 132: Autonomous AI Commercialization Framework
FIGURE 133: Enterprise IDN Contracting Framework
FIGURE 134: Reimbursement and Health Economic Evidence Framework
FIGURE 135: EHR Integration and Clinical Workflow Framework
FIGURE 136: Product Positioning and Portfolio Expansion Framework
FIGURE 137: Report Scope, Forecasting Limitations and Disclaimer Framework